Infections Requiring Hospitalization of Injection Drug Users Who Participated in an Injection Opiate Maintenance Program by Bassetti, Stefano et al.
BRIEF REPORTS • CID 2002:34 (1 March) • 711
B R I E F R E P O R T
Infections Requiring Hospitalization
of Injection Drug Users Who
Participated in an Injection Opiate
Maintenance Program
Stefano Bassetti,1 Matthias Hoffmann,2 Heiner C. Bucher,2
Ursula Fluckiger,1 and Manuel Battegay2
1Section of Infectious Diseases and 2Outpatient Department of Internal
Medicine, University Hospital Basel, Basel, Switzerland
A retrospective analysis of hospitalizations due to infection
in 175 injection drug users was performed for the 3 years
before and the period during their participation in an in-
jection opiate maintenance program (mean duration during
program, 2.6 years). Skin infections were the main reason
for hospitalization. The injection opiate maintenance pro-
gram did not reduce the incidence of infection leading to
hospitalization among the injection drug users studied.
Injection drug use is associated with several complications (e.g.,
infectious diseases, drug overdose, violence) that increase mor-
bidity and mortality rates for injection drug users (IDUs) [1–4].
Studies published elsewhere have demonstrated that infections
in particular are a leading cause of morbidity and hospitali-
zation among IDUs [3]. Complications associated with injec-
tion drug use are frequently the consequence of the illegal status
of street drugs. Therefore, opioid substitution programs were
developed, with the objective of reducing dependence and mor-
bidity and mortality rates associated with the use of psycho-
active substances.
In response to growing problem of the failure of oral sub-
stitution treatments to handle addiction in IDUs, injection opi-
ate maintenance programs were started [5–7]. These programs
are controversial [6]. Scientific evaluation of such programs is
therefore essential. It has been shown elsewhere that injection
opiate maintenance programs improved health status and social
Received 30 May 2001; revised 10 October 2001; electronically published 22 January 2002.
Financial support: canton of Basel City and an unrestricted educational grant (to S.B.) from
the AstraZeneca Fund of the Department of Internal Medicine, University Hospital Basel,
Basel, Switzerland.
Reprints or correspondence: Dr. Manuel Battegay, Outpatient Dept. of Internal Medicine,
University Hospital Basel, Petersgraben 4, CH-4031, Basel, Switzerland (mbattegay@uhbs.ch).
Clinical Infectious Diseases 2002; 34:711–3
 2002 by the Infectious Diseases Society of America. All rights reserved.
1058-4838/2002/3405-0025$03.00
functioning, reduced the self-reported use of illicit drugs and
criminal activity [5–7], and may decrease the incidence of HIV
and hepatitis A virus infection [8]. However, to our knowledge,
no data are available on the impact of such programs on severe
infections among the participants. The present report investi-
gates whether an injection opiate maintenance program de-
creases the incidence and changes the spectrum of infections
that require hospitalization among participating IDUs.
Patients and methods. This study is a retrospective analy-
sis of data from participants in the injection opiate maintenance
program in Basel, Switzerland, which began on 1 November
1994. Eligibility criteria for the opiate program were residence
in the canton of Basel City, age 20 years, a 2-year history
of addiction to injected heroin, failure of treatment for with-
drawal to cure addiction, and social distress and/or health prob-
lems that resulted from injection drug use. Participants had to
inject the prescribed drug (heroin, methadone, or morphine)
at the study site by using the clean equipment provided. At
enrollment in the program and at 6-month intervals, partici-
pants underwent psychiatric and somatic evaluations.
Written informed consent was obtained from all participants.
The study was approved by the Institutional Review Board of
the University of Basel, the canton of Basel City, and the Swiss
Federal authorities.
All participants who underwent their first evaluation from
1 November 1994 through 31 January 1997 are included in the
present analysis. Data regarding the hospitalizations of these
participants due to infection during the 3 years preceding the
enrollment in the injection opiate maintenance program were
compared with data for the hospitalizations that occurred dur-
ing the program. Hospitalizations were identified from the elec-
tronic patient records of the University Hospital Basel. After
identification of electronic records, patients charts were ex-
amined. University Hospital Basel provides primary and tertiary
care, and it is the only public hospital in the canton of Basel
City with a department of internal medicine. Very few IDUs
have access to any of the 3 private hospitals in the local area.
Therefore, University Hospital Basel admits 90% of all IDUs
residing in the canton of Basel City who require inpatient care
[2]. Hospitalizations that occurred from 1 November 1991
through 31 October 1998 were considered in the analysis.
The incidence of infection-related hospitalizations per 100
patient-years and the incidence ratio with 95% CIs were cal-
culated by use of Stata, version 6.0 (Stata Corporation).
Results. One hundred seventy-five IDUs (52 women and
123 men) were evaluated and admitted to the injection opiate
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Table 1. Infections requiring hospitalization of 175 injection
drug users before and during participation in an injection opiate
substitution program.
Infection site, type, or sign
No. of hospitalizations
(incidence per 100 patient-years)
Before admission
into program During program
Skina 20 (3.8) 21 (4.6)
Respiratory tractb 10 (1.9) 6 (1.3)
Bloodstreamc 5 (0.9) 3 (0.7)
Feverd 5 (0.9) 3 (0.7)
Hepatitise 3 (0.6) 0 (0)
HIV relatedf 2 (0.4) 2 (0.4)
Urogenitalg 0 (0) 3 (0.7)
Otherh 5 (0.9) 1 (0.2)
a Abscesses, phlegmonous infections, erysipelas, ulcerations, and necrosis.
b Pneumonia and pleural empyema.
c Isolated pathogens: Staphylococcus aureus ( ), Staphylococcus epi-np 4
dermidis ( ), Candida species and S. epidermidis coinfection ( ), Strep-np 1 np 1
tococcus pyogenes ( ), and Enterobacter cloacae ( ).np 1 np 1
d Without identification of a pathogen.
e Acute hepatitis A, acute hepatitis B, and newly discovered hepatitis C
with epigastric pain and pancytopenia.
f Diarrhea, encephalopathy, lymphadenitis, and Candida stomatitis.
g Pyelonephritis and epididymitis ( ).np 2
h Osteomyelitis, osteochondritis, septic thrombophlebitis, lymph-node ab-
scess, and surgical wound infections ( ).np 2
maintenance program in Basel from 1 November 1994 through
31 January 1997 and are included in the present analysis. The
mean age of patients at the time of enrollment in the program
was 31.4 years (range, 21–53 years), and the mean duration of
injection drug use was 11.8 years (range, 1.5–34 years). Of the
175 patients, 76 (43%) withdrew from the program before 31
October 1998. The reasons for withdrawal are known for 72
patients. The main reasons were admission to a conventional
oral opiate substitution program (22 patients), receipt of de-
toxification treatment (15 patients), and dissatisfaction with the
program (13 patients). Two of these 76 patients died during
the program: one patient died after injecting drugs outside the
program facility, and the other patient, who had AIDS, died of
pneumonia. The mean duration of participation in the program
was 2.6 years (range, 5 days to 4 years). Of the tested patients,
5 (2.9%) of 173 had chronic hepatitis B infection, 143 (82.2%)
of 174 had chronic hepatitis C infection (verified by hepatitis
C virus RNA determination), and 37 (21.5%) of 172 had HIV
infection.
Infections led to 50 hospitalizations among the 175 IDUs in
the 3-year period before admission to the injection opiate main-
tenance program, and they led to 39 hospitalizations while
patients were participating in the maintenance program (table
1). This resulted in an infection-related hospitalization rate of
9.5 hospitalizations per 100 patient-years before and 8.6 hos-
pitalizations per 100 patient-years during the program (inci-
dence ratio, 1.11; 95% CI, 0.71–1.73; ). Patients infectedPp .64
with HIV had significantly higher infection-related hospitali-
zation rates than did HIV-negative patients during, but not
before, the program (incidence per 100 patient-years during
the program, 8.0 in HIV-negative and 19.2 in HIV-positive
patients [incidence ratio, 0.42; 95% CI, 0.21–0.86; ];Pp .01
incidence before the program, 10.1 in HIV-negative and 14.4
in HIV-positive patients [incidence rate ratio, 0.70; 95% CI,
0.38–1.36; ]).Pp .25
Discussion. This retrospective analysis of a population of
severely addicted IDUs suggests that an injection opiate main-
tenance program may not significantly reduce the incidence of
infections that lead to hospitalization in this population in the
short term. Also, the type of infections that require hospitali-
zation observed in the present study did not change during the
injection opiate maintenance program. In fact, skin infection
remained the leading cause of hospitalization, followed by res-
piratory infection, bloodstream infection, and fever.
Several factors should be considered for a correct interpre-
tation of these findings. In the city of Basel, sterile injection
equipment is provided to all IDUs in state-supported public
facilities where illicit drug use is tolerated [2]. Thus, a majority
of IDUs included in the present analysis already routinely used
sterile injection equipment in these facilities before entering the
injection opiate maintenance program. This could explain the
similar incidence of skin infections that required hospitalization
before and during the program. On the other hand, the fact
that the incidence of infection-related hospitalizations during
the program did not increase may be interpreted as a stabili-
zation of the health status of the participants.
The medical assistance available during the program may
have permitted early identification and outpatient management
of infection, thus averting the need for hospitalization, but this
may have also contributed to the earlier hospitalization of at-
risk patients with severe comorbidity (in particular, HIV-pos-
itive patients). This is suggested by the data that showed a
decrease in infection-related hospitalization rates in HIV-neg-
ative patients, as opposed to an increase in infection-related
hospitalizations rates in HIV-positive patients, after enrollment
in the program. A randomized study with a control group
would be necessary to improve understanding of these factors.
However, this may not be feasible in severely addicted IDUs.
In addition to the use of nonsterile injection material, there
are other factors that may increase the risk of infections in
IDUs [3]: high prevalence of nasal Staphylococcus aureus carriers
among IDUs, poor dental hygiene, decreased bacterial clearance
by the tracheobronchial system during intoxication, impair-
ment of immune functions by heroin [9] or by injection drug
use itself, and promiscuity and prostitution. Only a few of these
factors may be influenced—and then only indirectly—by an
injection opiate maintenance program (e.g., through a decrease
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in the incidence of intoxication or a reduction in prostitution),
and an effect may be identified only with a longer follow-up
period.
The effect of an opiate maintenance program on the incidence
of chronic infection, such as HIV and hepatitis B and C virus
infection, is not considered in the present study. However, during
this injection opiate maintenance program, another study dem-
onstrated a low rate of seroconversion for HIV (only 1 new HIV
infection; incidence, 0.62 cases per 100 person-years), as well as
a considerable decrease in the hepatitis B and C virus serocon-
version rate after 6 months of participation in the program [8].
A relevant factor contributing to the decreased incidence of
bloodborne infections among IDUs is the reduction in the illicit
use of street drugs. Indeed, a reduction of illicit heroin use has
previously been shown among IDUs who participated in Swiss
injection opiate maintenance programs: at entry into the pro-
grams, 81% of the participants reported illicit heroin use on a
daily basis, whereas, at 18 months, only 6% of the participants
reported daily heroin use outside the program, and 74% reported
no illicit consumption of heroin [6, 7].
Seventy-six participants (43%) withdrew from the present
study. However, 37 of these 76 patients switched from the in-
jection opiate maintenance program to another form of treat-
ment (orally administered opiate substitution or detoxifica-
tion). It should also be noted that a retention rate of 57% after
a mean of 2.6 years should be considered a good result and is
comparable to the rate achieved in other studies [6, 7, 10].
In conclusion, an injection opiate maintenance program does
not directly decrease the incidence of infections requiring hos-
pitalization in the short term. However, other beneficial effects
of this kind of program, such as improvement of health status,
a decrease in the number of homeless persons, a reduction in
the consumption of street drugs [6, 7], and a decrease in the
incidence of HIV [8], are likely to reduce the risk of infection
among IDUs in the long term. These aspects need to be ad-
dressed in further studies.
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